Whitehawk Therapeutics (WHWK) EBIAT (2018 - 2025)
Whitehawk Therapeutics (WHWK) has disclosed EBIAT for 8 consecutive years, with -$17.7 million as the latest value for Q3 2025.
- On a quarterly basis, EBIAT fell 41.4% to -$17.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$15.6 million, a 74.74% increase, with the full-year FY2024 number at -$63.7 million, up 3.15% from a year prior.
- EBIAT was -$17.7 million for Q3 2025 at Whitehawk Therapeutics, up from -$52.6 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $73.0 million in Q1 2025 to a low of -$87.1 million in Q3 2021.
- A 5-year average of -$15.7 million and a median of -$16.0 million in 2021 define the central range for EBIAT.
- Peak YoY movement for EBIAT: crashed 2911.34% in 2021, then soared 499.23% in 2025.
- Whitehawk Therapeutics' EBIAT stood at -$16.0 million in 2021, then rose by 13.04% to -$13.9 million in 2022, then fell by 16.93% to -$16.3 million in 2023, then decreased by 12.32% to -$18.3 million in 2024, then rose by 3.13% to -$17.7 million in 2025.
- Per Business Quant, the three most recent readings for WHWK's EBIAT are -$17.7 million (Q3 2025), -$52.6 million (Q2 2025), and $73.0 million (Q1 2025).